Skip to content

Asarina Pharma AB (publ) Q4 / Year End 2020 report released

Asarina Pharma CEO Peter Nordkild: “2020 was a turbulent, challenging year for all of us – yet at Asarina Pharma we begin 2021 with continued confidence in the high potential of our flagship compound Sepranolone. We are on schedule to publish our topline results for our Phase IIa Menstrual Migraine study in June 2021, and in the same month initiate our Phase IIa study in Tourette syndrome.”


  • R&D costs reflecting termination of PMDD and CMC activities
  • Staff costs lower due to headcount reduction
  • Solid cash position at year-end



  • Our Phase IIa Menstrual Migraine study reached full recruitment in October 2020 with 164 patients recruited
  • The last patient was randomized on January 14, 2021
  • We are on schedule to publish topline results in June 2021


  • In February 2021, new preclinical Tourette syndrome data again demonstrated that Tourette-like manifestations in mice are mediated by Allopregnanolone, and significantly suppressed by Sepranolone
  • A preliminary, clean report from the juvenile tox study was received in mid-February confirming that we will be able to dose children and men with Sepranolone and Tourette syndrome following approval of our CTA from the Danish Medicines Agency
  • We expect to submit a CTA to the Danish Medicines Agency for our upcoming Phase IIa Tourette syndrome study in early March
  • We aim to initiate the study in June 2021